Close Menu

NEW YORK – A group led by researchers from the Broad Institute and Harvard Medical School found that liquid biopsy can capture a cancer's genetic heterogeneity not identified by tumor biopsies, as well as how cancer develops targeted drug resistance. 

The team therefore believes that liquid biopsy and standard tissue biopsy should be integrated to identify genetic alterations that lead to acquired resistance and eventually improve downstream therapeutic techniques.  

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.